227
mous cell carcinomas and esophageal adenocar-
cinomas reveals similarities and differences.
Oncologist 20(10):1132–1139. https://doi.
org/10.1634/theoncologist.2015-0156
- Fecteau RE, Kong J, Kresak A, Brock W, Song
Y, Fujioka H, Elston R, Willis JE, Lynch JP,
Markowitz SD, Guda K, Chak A (2016)
Association between germline mutation in
VSIG10L and familial Barrett neoplasia. JAMA
Oncol 2(10):1333–1339. https://doi.
org/10.1001/jamaoncol.2016.2054
- Bian YS, Osterheld MC, Fontolliet C, Bosman
FT, Benhattar J (2002) p16 inactivation by
methylation of the CDKN2A promoter occurs
early during neoplastic progression in Barrett’s
esophagus. Gastroenterology
122(4):1113–1121
- Silvers AL, Lin L, Bass AJ, Chen G, Wang Z,
Thomas DG, Lin J, Giordano TJ, Orringer
MB, Beer DG, Chang AC (2010) Decreased
selenium-binding protein 1 in esophageal ade-
nocarcinoma results from posttranscriptional
and epigenetic regulation and affects chemo-
sensitivity. Clin Cancer Res 16(7):2009–2021.
https://doi.org/10.1158/1078-0432.
ccr-09-2801
- Bian YS, Osterheld MC, Bosman FT, Benhattar
J, Fontolliet C (2001) p53 gene mutation and
protein accumulation during neoplastic pro-
gression in Barrett’s esophagus. Mod Pathol
14(5):397–403. https://doi.org/10.1038/
modpathol.3880324
- Stachler MD, Taylor-Weiner A, Peng S,
McKenna A, Agoston AT, Odze RD, Davison
JM, Nason KS, Loda M, Leshchiner I, Stewart
C, Stojanov P, Seepo S, Lawrence MS, Ferrer-
Torres D, Lin J, Chang AC, Gabriel SB, Lander
ES, Beer DG, Getz G, Carter SL, Bass AJ
(2015) Paired exome analysis of Barrett’s
esophagus and adenocarcinoma. Nat Genet
47(9):1047–1055. https://doi.org/10.1038/
ng.3343
- Dolan K, Walker SJ, Gosney J, Field JK, Sutton
R (2003) TP53 mutations in malignant and
premalignant Barrett’s esophagus. Dis
Esophagus 16(2):83–89
- Doak SH, Jenkins GJ, Parry EM, Griffiths AP,
Shah V, Baxter JN, Parry JM (2003)
Characterisation of p53 status at the gene,
chromosomal and protein levels in esophageal
adenocarcinoma. Br J Cancer 89(9):1729–
1735. https://doi.org/10.1038/sj.
bjc.6601323
- Chung SM, Kao J, Hyjek E, Chen YT (2007)
p53 in esophageal adenocarcinoma: a critical
reassessment of mutation frequency and identi-
fication of 72Arg as the dominant allele. Int
J Oncol 31(6):1351–1355
14. Novotna K, Trkova M, Pazdro A, Smejkal M,
Soukupova A, Kodetova D, Smejkal P, Sedlacek
Z (2006) TP53 gene mutations are rare in
nondysplastic Barrett’s esophagus. Dig Dis Sci
51(1):110–113. https://doi.org/10.1007/
s10620-006-3093-3
15. Del Portillo A, Lagana SM, Yao Y, Uehara T,
Jhala N, Ganguly T, Nagy P, Gutierrez J,
Luna A, Abrams J, Liu Y, Brand R, Sepulveda
JL, Falk GW, Sepulveda AR (2015) Evaluation
of mutational testing of preneoplastic Barrett’s
mucosa by next-generation sequencing of for-
malin-fixed, paraffin-embedded endoscopic
samples for detection of concurrent dysplasia
and adenocarcinoma in Barrett’s esophagus.
J Mol Diagn 17(4):412–419. https://doi.
org/10.1016/j.jmoldx.2015.02.006
16. Galipeau PC, Li X, Blount PL, Maley CC,
Sanchez CA, Odze RD, Ayub K, Rabinovitch
PS, Vaughan TL, Reid BJ (2007) NSAIDs
modulate CDKN2A, TP53, and DNA content
risk for progression to esophageal adenocarci-
noma. PLoS Med 4(2):e67. https://doi.
org/10.1371/journal.pmed.0040067
17. Madani K, Zhao R, Lim HJ, Casson AG (2010)
Prognostic value of p53 mutations in esopha-
geal adenocarcinoma: final results of a 15-year
prospective study. Eur J Cardiothorac Surg
37(6):1427–1432. https://doi.
org/10.1016/j.ejcts.2009.12.018
18. Casson AG, Evans SC, Gillis A, Porter GA,
Veugelers P, Darnton SJ, Guernsey DL,
Hainaut P (2003) Clinical implications of p53
tumor suppressor gene mutation and protein
expression in esophageal adenocarcinomas:
results of a ten-year prospective study. J Thorac
Cardiovasc Surg 125(5):1121–1131. https://
doi.org/10.1067/mtc.2003.176
19. Rajendra S, Wang B, Merrett N, Sharma P,
Humphris J, Lee HC, Wu J (2016) Genomic
analysis of HPV-positive versus HPV-negative
esophageal adenocarcinoma identifies a differ-
ential mutational landscape. J Med Genet
53(4):227–231. https://doi.org/10.1136/
jmedgenet-2015-103411
20. Astori G, Merluzzi S, Arzese A, Brosolo P, de
Pretis G, Maieron R, Pipan C, Botta GA (2001)
Detection of human papillomavirus DNA and
p53 gene mutations in esophageal cancer sam-
ples and adjacent normal mucosa. Digestion
64(1):9–14. https://doi.
org/10.1159/000048834
21. Wijnhoven BP, de Both NJ, van Dekken H,
Tilanus HW, Dinjens WN (1999) E-cadherin
gene mutations are rare in adenocarcinomas of
the esophagus. Br J Cancer 80(10):1652–
1657. https://doi.org/10.1038/sj.
bjc.6690577
Single Gene Mutation in Esophageal Adenocarcinoma
